Prognostic significance of FLT3 mutation status in APL
. | Total . | WT . | ITD* . | P . | D835/I836 only . | P . | Either mutant . | P . |
|---|---|---|---|---|---|---|---|---|
| No. | 203 | 115 | 69 | 19 | 88 | |||
| ID, % | 13 | 9 | 17 | .10 | 26 | .04 | 19 | .04 |
| OR (95% Cl) | — | — | 2.27 (0.91-5.68) | 5.81 (1.25-26.9) | 2.50 (1.11-5.65) | |||
| RD, % | 2 | 3 | 1 | .7 | 5 | .5 | 2 | .7 |
| OR (95% Cl) | — | — | 0.47 (0.07-2.91) | 1.64 (0.13-21.0) | 0.66 (0.13-3.38) | |||
| CR, % | 84 | 88 | 81 | .3 | 68 | .04 | 78 | .09 |
| OR (95% Cl) | — | — | 1.70 (0.73-3.94) | 4.56 (1.17-17.7) | 1.99 (0.94-4.22) | |||
| Outcome at 5 y | ||||||||
| RR at 5 y, % | 25 | 23 | 28 | .5 | 25 | .9 | 28 | .5 |
| OR (95% Cl) | — | — | 1.29 (0.65-2.53) | 1.06 (0.31-3.62) | 1.24 (0.66-2.34) | |||
| OS at 5 y, % | 64 | 67 | 62 | .5 | 47 | .05 | 59 | .2 |
| OR (95% Cl) | — | — | 1.19 (0.72-1.98) | 2.55 (1.09-5.98) | 1.36 (0.86-2.15) |
. | Total . | WT . | ITD* . | P . | D835/I836 only . | P . | Either mutant . | P . |
|---|---|---|---|---|---|---|---|---|
| No. | 203 | 115 | 69 | 19 | 88 | |||
| ID, % | 13 | 9 | 17 | .10 | 26 | .04 | 19 | .04 |
| OR (95% Cl) | — | — | 2.27 (0.91-5.68) | 5.81 (1.25-26.9) | 2.50 (1.11-5.65) | |||
| RD, % | 2 | 3 | 1 | .7 | 5 | .5 | 2 | .7 |
| OR (95% Cl) | — | — | 0.47 (0.07-2.91) | 1.64 (0.13-21.0) | 0.66 (0.13-3.38) | |||
| CR, % | 84 | 88 | 81 | .3 | 68 | .04 | 78 | .09 |
| OR (95% Cl) | — | — | 1.70 (0.73-3.94) | 4.56 (1.17-17.7) | 1.99 (0.94-4.22) | |||
| Outcome at 5 y | ||||||||
| RR at 5 y, % | 25 | 23 | 28 | .5 | 25 | .9 | 28 | .5 |
| OR (95% Cl) | — | — | 1.29 (0.65-2.53) | 1.06 (0.31-3.62) | 1.24 (0.66-2.34) | |||
| OS at 5 y, % | 64 | 67 | 62 | .5 | 47 | .05 | 59 | .2 |
| OR (95% Cl) | — | — | 1.19 (0.72-1.98) | 2.55 (1.09-5.98) | 1.36 (0.86-2.15) |
Percentages may not add up to 100% because of rounding. All comparisons are made with the WT group.
ID indicates induction death; OR, odds ratio; Cl, confidence interval; RD, resistant disease; CR, complete remission; RR, relapse risk; OS, overall survival; —, not applicable.
Includes 4 patients with coexistent FLT3 ITD and D835/I836 mutation.